Efficacy of duplizumab in the treatment of multiple type 2 inflammatory diseases
10.3760/cma.j.cn431274-20210412-00414
- VernacularTitle:度普利尤单抗治疗合并多种2型炎症疾病的疗效分析
- Author:
Jiaxing XIE
1
;
Huimin LIN
;
Xiaoxian ZHANG
;
Qingling ZHANG
Author Information
1. 广州医科大学附属第一医院呼吸与危重症医学科，广州呼吸健康研究院，国家呼吸系统疾病临床医学研究中心，呼吸疾病国家重点实验室，广州 510120
- Keywords:
Asthma;
Dermatitis, atopic;
Sinusitis;
Type 2 inflammatory;
Dupilumab
- From:
Journal of Chinese Physician
2022;24(3):350-354
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the therapeutic effect of adding interleukin (IL)-4Rα monoclonal antibody (duplizumab) to patients with multiple types of inflammatory diseases.Methods:Six patients with multiple types of inflammatory diseases who started to use duplizumab from August 2020 were enrolled. The changes of airway inflammation, lung function, sinuses computed tomography (CT), Asthma Control Questionnaire-5 (ACQ-5), Sino-Nasal Outcome Test-22 (SNOT-22), Pennsylvania Smell Identification Test (UPSIT) and Numerical Rating Scale (NRS) score before and after duplizumab treatment were retrospectively analyzed. All patients were treated with doprilumab for more than 5 months.Results:4 of the 6 patients had both severe asthma and chronic sinusitis, and 2 patients had both severe asthma, chronic sinusitis and atopic dermatitis. After treatment, the pulmonary function of 6 patients was improved, the levels of sputum eosinophils, exhaled nitric oxide and total IgE were decreased (all P<0.05), and the scores of paranasal sinus CT, ACQ-5, SNOT-22 and UPSIT were significantly improved (all P<0.05). However, 3 patients had increased peripheral blood eosinophils during the treatment. Conclusions:Duplizumab is effective for a variety of type 2 inflammatory diseases without obvious adverse reactions, and the peripheral eosinophils may increase during the treatment.
